PTH and Hypercalcemia: Due to concerns about hypercalcemia and oversuppression parathyroid hormone (PTH), a synthetic vitamin D analogue (paricalcitol), a noncalcium-containing phosphate binder (sevelamer), and a calcimimetic (cinacalcet) have entered the market since 1998, 1998, and 2004, respectively.